Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update
Fourth Quarter 2024 and Recent Developments: The Phase 2 Tailwind study represents the second successful clinical trial for AP-PA02, Armata's lead pulmonary candidate, which was first evaluated in ...
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year
Reports Q4 grant revenue $1.2M vs $1.5M last year. “During the fourth quarter, we achieved another significant clinical milestone with ...
Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...
A doctor you can text, call, and see within a day? Inside the growing model of ‘direct primary care.’
Proponents herald the practice as a free-market approach to providing medical care, while critics say it could widen health ...